Safety matters and contraindications that need to be paid attention to when taking abatacept (Enresu)

Abatacept (trade name: Orencia) is an immunomodulator that belongs to the fusion protein class. It modulates the immune response by inhibiting T cell co-stimulatory signals, thereby reducing the inflammatory response of autoimmune diseases. The drug is mainly used to treat moderate to severe rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and the prevention of chronic transplant rejection. Although abatacept has significant clinical efficacy, due to its immunosuppressive effect, a series of safety precautions need to be paid attention to during medication, and contraindications must be strictly observed to reduce the risk of adverse events.

The risk of infection is one of the most important safety considerations while using abatacept. By inhibiting TT cell activation, abatacept may lead to a decrease in patients' resistance to various pathogens and increase the risk of respiratory tract infections, urinary tract infections and serious opportunistic infections. Before taking medication, doctors usually assess the patient's past infection history and, if necessary, screen for infectious diseases such as tuberculosis, hepatitis B, and hepatitis C. During the treatment process, if the patient develops fever, cough, difficulty breathing or other symptoms of infection, he should seek medical treatment immediately and suspend medication according to the situation. It should be used with caution and closely monitored for signs of infection in patients with a history of chronic or recurrent infections.

Immune-related complications are also safety issues that need to be paid attention to during medication. Abatacept may cause lymphopenia, thrombocytopenia, and abnormal immune responses. Patients should have regular blood routine, liver and kidney function monitoring during medication so that potential abnormalities can be detected early and the dose can be adjusted or medication discontinued in a timely manner. In addition, for patients with autoimmune diseases (such as systemic lupus erythematosus, Crohn's disease, etc.), the risks of using abatacept should be carefully evaluated, because the drug may aggravate the original immune disorder or induce new autoimmune reactions.

Anaphylaxis and injection site reactions are also common adverse effects of abatacept. During intravenous or subcutaneous injection, some patients may experience local reactions such as redness, swelling, pain or itching, and a few patients may experience systemic allergic reactions, including rash, difficulty breathing or hypotension. In the event of a severe allergic reaction, the medication should be stopped immediately and first aid treatment should be provided. Before taking the drug for the first time, a small dose trial can be used to observe the patient's tolerance and reduce risks.

Abatacept is contraindicated in people who are allergic to the drug ingredients, patients with active infections, and patients with severe heart failure. In addition, pregnant and lactating women should use it with caution and decide whether to use it after weighing the pros and cons. For patients taking other immunosuppressants concomitantly (such as cyclosporine, methotrexate, glucocorticoids, etc.), special attention should be paid to drug interactions that may increase the risk of infection and hematological abnormalities.

Overall, abatacept has important efficacy in the prevention of autoimmune diseases and transplant rejection, but safe management during treatment is crucial. Patients need to undergo a comprehensive assessment before treatment, including infection risk, hematological indicators, and past disease history; infection symptoms, blood routine, and liver and kidney function should be closely monitored during treatment; if abnormal reactions occur, the drug should be discontinued or the plan should be adjusted in time. At the same time, regulations on contraindicated groups should be strictly observed and the risks of combined medication should be reasonably assessed. Through scientific safety management and regular follow-up, abatacept can maximize the efficacy while minimizing the risk of adverse events, providing patients with a stable and effective treatment option.

Reference link:https://www.drugs.com